RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Results of Operations and Financial Condition

RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operation and Financial Condition

Story continues below

On March 19, 2018, Ritter Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period and full year ending December 31, 2017, entitled “Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update” (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of Section 18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18. Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such filings.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits


RITTER PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex99-1.htm   Exhibit 99.1    Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update   LOS ANGELES (March 19,…
To view the full exhibit click here

About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

An ad to help with our costs